MedPharm is pleased to announce that it has been selected as a finalist in two CPHI Pharma Award Categories.
MedPharm’s unique MedSpray® Aerosol Technology was shortlisted for the Finished Formulation category, and our MedCast model was shortlisted in the Drug Delivery Device Innovation category.
Guildford, UK and Durham, NC, February 20, 2024 – MedPharm, a global topical and transdermal CDMO, today announced several Board changes, including the appointment of Patrick Walsh as Executive Chairman. Patrick has been an Ampersand Operating Partner for the last 10 years, served as CEO of three Ampersand CDMO investments, and is currently Chairman of Alcami and ANI Pharmaceuticals.
Minor Hinson of Bourne Partners Strategic Capital (“BPSC”) also joined the MedPharm Board of Directors. Minor is the Head of Private Equity and Chief Investment Officer (CIO) of BPSC and has served on the Boards of a variety of pharmaceutical and pharma services businesses, including Covis Pharma (BPSC was co-founder with the original management team), PAI Pharmaceuticals and Eximia Research Network.
MedPharm, a global CDMO focused on topical and transdermal development and manufacturing, recently announced the appointment of a new U.S. Director of Analytical, Monica Germann, and the restructuring of its analytical suite in the U.S. This appointment, as well as the restructuring of the department, will create new growth opportunities for the organization, as well as efficiency gains and harmonization of analytical services across all MedPharm sites.
MedPharm currently provides a comprehensive range of analytical and bioanalytical method development and validation services to the pharmaceutical industry. This department restructure, which includes combining MedPharm’s analytical and bioanalytical teams, will allow the CDMO to build on its existing LC-MS/MS, LCUV, UPLC, and qRT-PCR testing services.
MedPharm, a global provider of contract topical and transdermal formulation development and manufacturing services, is pleased to announce that it will support Swiss Biotech company, Mosanna Therapeutics, in the development of a nasal spray (MOS-118) aimed at treating Metabolic Obstructive Sleep Apnea (MOSA).
The collaboration will focus on advancing MOS-118 into clinical development. Mosanna is developing MOS-118 to prevent the airway from collapsing during sleep in a disease that affects up to 1 billion globally. The repeated partial or complete obstruction of the upper airway during sleep is associated with adverse metabolic and cardiovascular events and can severely impact the quality of life for patients.
MedPharm, a global Contract Development and Manufacturing Organization that specializes in topical and transdermal drug product development, recently completed a Medicines and Healthcare products Regulatory Agency (MHRA) GMP audit of its Guildford locations. We are happy to announce there were no critical or major findings from the audit.
These evaluations of MedPharm’s systems and compliance with regulatory standards are further confirmation of MedPharm’s commitment to providing the gold standard in topical development and manufacturing services.
To learn more about MedPharm’s capabilities, view our virtual facility tours or contact our team today.
